Management of Upper Gastrointestinal Bleeding with Terlipressin

Introduction to Terlipressin Therapy

The American Association for the Study of Liver Diseases recommends that terlipressin should be initiated immediately as soon as variceal bleeding is suspected in cirrhotic patients with upper GI bleeding, even before endoscopic confirmation, and continued for 2-5 days as adjuvant therapy to endoscopic band ligation 1, 2

Terlipressin reduces bleeding-related mortality by 34% compared to placebo (relative risk 0.66, 95% CI 0.49-0.88) and decreases failure to control initial hemostasis by 34% 2
Terlipressin is superior to vasopressin alone and equivalent to the combination of vasopressin plus nitroglycerin in controlling variceal bleeding 3, 4

Initial dosing of terlipressin is 2 mg IV every 4 hours for the first 48 hours until bleeding is controlled, as recommended by the European Association for the Study of the Liver 1, 2
Maintenance dosing of terlipressin is 1 mg IV every 4 hours after the initial 48-hour period 1, 2

The American College of Gastroenterology recommends immediate initiation of terlipressin as soon as variceal bleeding is suspected, before diagnostic endoscopy, and concurrent administration of prophylactic antibiotics (ceftriaxone 1g IV daily or norfloxacin) 1, 2
Volume resuscitation should be performed using crystalloids with a restrictive transfusion strategy (hemoglobin threshold 7 g/dL, target 7-9 g/dL), as suggested by the International Society on Thrombosis and Haemostasis 1, 6

Terlipressin is the preferred vasoactive agent when available due to its proven mortality benefit, which has not been consistently demonstrated with somatostatin or octreotide, according to the American Association for the Study of Liver Diseases 2

Absolute contraindications to terlipressin include pregnancy, active coronary, peripheral, or mesenteric ischemia, and hypoxia or worsening respiratory symptoms, as stated by the European Medicines Agency 5, 7
Relative contraindications include cardiac conditions or coronary artery disease, and progressive hypotension (systolic BP <90 mmHg), as noted by the American Heart Association 1, 2, 6

In cases of refractory bleeding, the American College of Gastroenterology recommends proceeding to early transjugular intrahepatic portosystemic shunt (TIPS) placement, particularly in high-risk patients 1, 2